Blog Posts - Easl 2015



Our Expert Picks: Critical Data From EASL‏ 2015

2015 Meeting of the European Association for the Study of the Liver Independent Conference Coverage* Jordan J. Feld, MD, MPH Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF Andrew J. Muir, MD David R.... Monday HCV News Ticker- Hepatitis C: Coffee, M...
by HCV New Drug Research on Apr 28, 2015

Merck Announces Presentation of Phase 2 Clinical Trial Results of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir at the International Liver Congress™ 2015

Results of C-SALVAGE Study Showed High Sustained Virologic Response Rates in Patients Who Failed Prior Combination Therapy with Certain Direct Acting Antiviral (DAA) Agents Results of C-SWIFT Study Provide Proof-of-Concept for Shorter Than Twelve We...
by Hepatitis C Research and News on Apr 25, 2015

ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B)

97% of post-transplant patients with HCV genotype 1a achieved cure 91% of post-transplant patients with HCV genotype 3 achieved cure  No need seen to alter existing transplantation medication regimens Saturday, April 25, 2015 10:00 am EDT...
by Hepatitis C Research and News on Apr 25, 2015

Cancer rates among patients with hepatitis C are increased compared to those not infected

Public Release: 24-Apr-2015 Researchers suggest an extrahepatic manifestation of hepatitis C may be an increased risk of cancer European Association for the Study of the Liver April 24, 2015, Vienna , Austria: Results announced today at The Intern...
by Hepatitis C Research and News on Apr 25, 2015

Gilead Announces Results From Studies Evaluating Sofosbuvir-Based Regimens in Chronic Hepatitis C Patients With Genotypes 2-5

-- High Cure Rates Observed Across a Range of Genotypes -- VIENNA, Austria--(BUSINESS WIRE)--Apr. 25, 2015-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from two studies evaluating the safety and efficacy of investigational uses of...
by Hepatitis C Research and News on Apr 25, 2015

Merck’s Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection

Data Sets Include Treatment-Naïve, Treatment-Experienced and HIV Co-Infected Patients with Chronic Hepatitis C Virus Genotypes 1, 4 or 6 Infection Merck Remains on Track to Submit New Drug Application (NDA) to U.S. Food and Drug Administration (FDA...
by Hepatitis C Research and News on Apr 24, 2015

U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C

- The New Drug Application (NDA) was accepted by the U.S. Food and Drug Administration (FDA) and is based on results from the PEARL-I study, which demonstrated up to 100 percent sustained virologic response rates at 12 weeks post-treatment with no di...
by Hepatitis C Research and News on Apr 24, 2015

Enanta Announces U.S. FDA Grants Priority Review for AbbVie’s Investigational, All-Oral, Interferon-Free Treatment Regimen for Genotype 4 Chronic Hepatitis C Infection

April 23, 2015 08:16 AM Eastern Daylight Time WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and...
by Hepatitis C Research and News on Apr 23, 2015

Positive preclinical antiviral and safety profile of MIV-802 supports continued development

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announce that the preclinical antiviral and safety profile of MIV-802, Medivir’s wholly-owned nucleotide polymerase inhibitor under development for the treatment of hepatitis C virus (...
by Hepatitis C Research and News on Apr 23, 2015

Civacir can effectively prevent HCV recurrence following liver transplants

Published on April 23, 2015 at 6:50 AM New data from an ongoing Phase III trial revealed today at The International Liver CongressTM 2015 show that the use of hepatitis C immune globulin (HCIG, Civacir®) can effectively prevent hepatitis C virus (H...
by Hepatitis C Research and News on Apr 23, 2015

Merck Announces Results from Phase 2/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir in Patients with Advanced Chronic Kidney Disease

C-SURFER Trial is First to Investigate an All-Oral Ribavirin-Free Hepatitis C Treatment Regimen in Treatment-Naïve and Treatment-Experienced Patients with Advanced Chronic Kidney Disease Infected with Hepatitis C Virus Genotype 1 Thursday, April 2...
by Hepatitis C Research and News on Apr 23, 2015

Janssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis

- Data from OPTIMIST-1 and OPTIMIST-2 Trials Showing SVR12 Rates of 97 Percent and 84 Percent to be Presented at The International Liver Congress™ 2015 of the European Association for the Study of the Liver - CORK, Ireland, April 23, 2015 /PRNewsw...
by Hepatitis C Research and News on Apr 23, 2015

Study reveals impact of delaying HCV treatment

Published on April 23, 2015 at 4:01 AM Data revealed today at The International Liver Congress™ 2015 highlights the impact of delaying treatment for the hepatitis C virus (HCV). Researchers found that treatment delays have a serious detrimental ef...
by Hepatitis C Research and News on Apr 23, 2015

Shorter HCV Tx Works in Advanced Disease

Provided by MedPage Today Twelve weeks of treatment yielded high efficacy rates in hepatitis C (HCV) patients with advanced liver disease or recurrent HCV after transplant. by Michael Smith North American Correspondent, MedPage Today VIENNA --...
by Hepatitis C Research and News on Apr 23, 2015

Patients feel stigma, discrimination when living with hepatitis

Provided by Healio April 23, 2015 VIENNA — After receiving their diagnoses, patients with viral hepatitis report suffering stigma and discrimination at the hands of family, friends, employers and even health care practitioners, according to a sur...
by Hepatitis C Research and News on Apr 23, 2015

Gilead Announces Data for Investigational, All-Oral, Pan-Genotypic Three-Drug Regimen of Sofosbuvir, GS-5816 and GS-9857 for Chronic Hepatitis C

-- Data Support Ongoing Trials Evaluating Shortened Course of Therapy -- VIENNA, Austria--(BUSINESS WIRE)--Apr. 23, 2015-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced pre-clinical data and results from Phase 1 and Phase 2 studies supporting...
by Hepatitis C Research and News on Apr 23, 2015

The EASL Releases New Recommendations on the Treatment of Hepatitis C 2015

April 21, 2015 The European Association for the Study of the Liver releases new recommendations for treating Hepatitis C. “These EASL Recommendations on Treatment of Hepatitis C are intended to assist physicians and other healthcare providers, as...
by Hepatitis C Research and News on Apr 22, 2015

EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis

Journal of Hepatology Available online 21 April 2015 In Press, Corrected Proof — Note to users Clinical Practice Guidelines European Association for the Study of the Liver, easloffice@easloffice.eu   Asociacion Latinoamericana para...
by Hepatitis C Research and News on Apr 22, 2015

Hepatitis C Will Share Spotlight This Year at Liver Congress

Medscape Medical News > Conference News Miriam E. Tucker April 17, 2015 Hepatitis C will again be a hot topic at this year's European Association for the Study of the Liver (EASL) International Liver Congress, but other subjects, such as nonalc...
by Hepatitis C Research and News on Apr 17, 2015

A pre-EASL look at the current landscape of ongoing HCV research

Provided by citeline April 16, 2015 | Doro Shin On 26 April 2015, the International Liver Conference, also referred to as EASL, will be convening for its 50th year in Vienna. This year, the organizers offered a new abstract category named “Clinic...
by Hepatitis C Research and News on Apr 16, 2015


Trending Topics

Close